[Federal Register Volume 62, Number 246 (Tuesday, December 23, 1997)]
[Notices]
[Pages 67088-67089]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-33384]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Pharmaceutical 
Compositions And Methods For Treatment of Hyperproliferative Epithelial 
Skin Diseases and Cancer

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. Sec. 209(c)(1) and 
37 CFR 404.7(a)(1)(I) that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive worldwide license to practice the inventions embodied in 
the U.S. Patent Application SN 07/677,429 ``Pharmaceutical Compositions 
And Methods For Preventing Skin Tumor Formation And Causing Regression 
Of Existing Tumors'' filed 3/29/91 and U.S. Patent Application SN 08/
389,845 ``Method For The Treatment Of Hyperproliferative Epithelial 
Skin Disease By Topical Application Of Hydroxylated Aromatic Protein * 
* *'' filed 2/2/95 now U.S. Patent 5,610,185 issued 3/11/97 to Nascent 
Pharmaceuticals, L.L.C. of San Francisco, CA. The patent rights in this 
invention have been assigned to the United States of America.
    The prospective exclusive license field of use may be limited to: 
Therapeutics for treatment and prevention of various hyperproliferative 
skin diseases in humans.

DATE: Only written comments and/or applications for a license which are 
received by NIH on or before March 23, 1998 will be considered.

ADDRESS: Requests for copies of the patent or patent application, 
inquiries, comments and other materials relating to the contemplated 
licenses should be directed to: Joseph G. Contrera, M.S., J.D., 
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; Telephone: (301)

[[Page 67089]]

496-7056 ext. 244; Facsimile (301) 402-0220. A signed Confidentiality 
Agreement will be required to receive copies of the patent application.

SUPPLEMENTARY INFORMATION:
The 07/677,429 (`429) invention describes the use of Staurosporine and 
closely related compounds in treating precancerous conditions of the 
skin by topical application. Staurosporine has been known for at least 
a decade as an inhibitor of protein kinase C, a major cellular enzyme 
involved in cell signalling and second messenger systems.
    The 08/389,845 (`845) invention is directed towards a method of 
treating hyperproliferative epithelial cell lesions by topical 
application of hydroxylated aromatic protein cross-linking compounds 
which are derived from cinnamic acid. These compounds utilize dual 
methods of action, that is, growth inhibition and protein cross 
linking. Both the `429 and `845 inventions may be applied towards a 
wide range of skin disorders, including warts, cervical tumors, pre-
malignant lesions, basal carcinomas and squamous carcinomas.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. Sec. 209 and 37 CFR 
404.7. The prospective exclusive license may be granted unless within 
ninety (90) days from the date of this published notice, NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 
Sec. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated licenses. Comments and objections submitted to this notice 
will not be made available for public inspection and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. Sec. 552.

    Dated: December 9, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-33384 Filed 12-22-97; 8:45 am]
BILLING CODE 4140-01-M